Qualit-E-SpeakPharma-Insert
X

Find Approved Neurology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ozanimod

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 27, 2020

            Details:

            The CHMP adopted the positive opinion based on data from the randomized, active-controlled Phase 3 SUNBEAM™ and RADIANCE™ Part B clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: JMP Securities LLC

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 24, 2020

            Details:

            Baudax intends to use the net proceeds of the proposed offering for the launch and the commercialization of ANJESO™, pipeline development activities, and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gabapentin

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Assertio Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger March 16, 2020

            Details:

            The Merger will create a leading commercial pharmaceutical company with neurology, inflammation and pain products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amlodipine Besylate,Celecoxib

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Coeptis Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 11, 2020

            Details:

            Burke will market the fixed-dose combination drug, Consensi to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camphor,Capsicum oleoresin,Menthol

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Angelini Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 10, 2020

            Details:

            The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Limaprost Alfadex

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nichi-Iko Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 05, 2020

            Details:

            Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg to a formulation which has been improved for moisture resistance stability following the technology transfer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRM-151,Meloxicam

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing March 04, 2020

            Details:

            Strategic financing to provide funding for the commercial launch of ANJESO.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Caffeine,Isometheptene,Metamizole Sodium

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hypera S.A.

            Deal Size: $825.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment March 02, 2020

            Details:

            The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapentadol

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Collegium Pharmaceutical

            Deal Size: $375.0 million Upfront Cash: $375.0 million

            Deal Type: Agreement February 06, 2020

            Details:

            Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine Hydrochloride

            Therapeutic Area: Neurology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sandoz

            Deal Size: $440.0 million Upfront Cash: $330.0 million

            Deal Type: Acquisition January 31, 2020

            Details:

            The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan.